Maven's MBO Fund II has committed up to £15 million to support Covestus' acquisition strategy aimed at expanding its portfolio in the consumer healthcare market.

Target Company Overview

Covestus is a rapidly expanding consumer healthcare group headquartered in Cheltenham. The company focuses on developing and managing brands that possess strong clinical credentials, all while pursuing opportunities to enhance brand recognition, improve product distribution, and foster new product development. Among its existing portfolio are notable brands like Probio7, a leading gut health supplement, and Sweatguard, a clinically proven treatment for hyperhidrosis. The recent investment targets the acquisition of two well-established oral care brands: UltraDEX, a clinically supported halitosis treatment range, and Dentyl, a prominent mouthwash brand, thereby enhancing Covestus's footprint in the oral care segment.

Industry Overview

The consumer healthcare market in the UK is witnessing significant growth, propelled by a surging demand for self-care and wellness solutions. People are increasingly inclined to invest in healthcare products that address chronic conditions and preventative health needs. This trend is particularly prevalent in sectors such as oral care, where consumers seek effective solutions backed by scientific evidence.

As a result of this growing consumer focus, companies like Covestus are well-positioned to capitalize on market trends. The acquisition of high-demand brands not only enhances their market portfolio but also allows for the integration of inn